NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

失養型表皮分解性水泡症治療藥的全球市場:產業分析,市場規模、佔有率、成長率、趨勢、預測 (2020年∼2030年)

Dystrophic Epidermolysis Bullosa Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

出版商 Transparency Market Research 商品編碼 980304
出版日期 內容資訊 英文 168 Pages
商品交期: 最快1-2個工作天內
價格
失養型表皮分解性水泡症治療藥的全球市場:產業分析,市場規模、佔有率、成長率、趨勢、預測 (2020年∼2030年) Dystrophic Epidermolysis Bullosa Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030
出版日期: 2020年11月26日內容資訊: 英文 168 Pages
簡介

本報告提供全球失養型表皮分解性水泡症治療藥的市場相關分析,市場基本結構和主要的影響要素,市場規模趨勢預測 (過去2年、今後11年份),治療藥的各類型、疾病的各類型、各流通管道及各地區詳細趨勢,競爭環境 (市場佔有率結構),主要企業簡介等調查。

目錄

第1章 序文

第2章 前提條件與分析方法

第3章 摘要整理:全球失養型表皮分解性水泡症治療藥市場

第4章 市場概要

  • 簡介
    • 失養型表皮分解性水泡症治療藥:市場概要
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 全球失養型表皮分解性水泡症治療藥市場分析、預測 (2018年∼2030年)
    • 市場收益額,預測值 (單位:百萬美元)

第5章 主要考察

  • 治療失養型表皮分解性水泡症的新治療方法
  • 開發平台分析
  • 第三階段開發平台藥物療法的潛在市場
  • 失養型表皮分解性水泡症的流行病學
  • 近來的產業主要趨勢(M&A (企業合併、收購),事業合作,產品核可等)
  • 新型冠狀病毒感染疾病 (COVID-19)對產業的影響 (價值鏈及短期/中期/長期性影響)

第6章 全球失養型表皮分解性水泡症治療藥市場:治療藥的各種類分析、預測

  • 簡介、定義
  • 主要的分析結果/趨勢
  • 市場規模:治療藥的各類型 (2018年∼2030年)
    • 抗生素
    • 皮質類固醇
    • 類鴉片物質止痛藥
    • 抗痙攣藥
    • 其他
  • 市場向心力分析:治療藥的各類型

第7章 全球失養型表皮分解性水泡症治療藥市場:疾病的各種類分析、預測

  • 簡介、定義
  • 主要的分析結果/趨勢
  • 市場規模:疾病的各類型 (2018年∼2030年)
      • 顯性失養型表皮分解性水泡症
      • 隱性失養型表皮分解性水泡症
    • 市場向心力分析:疾病的各類型

    第8章 全球失養型表皮分解性水泡症治療藥市場:各流通管道分析、預測

    • 簡介、定義
    • 主要的分析結果/趨勢
    • 市場規模:各流通管道 (2018年∼2030年)
      • 醫院藥局
      • 零售藥局
      • 其他
    • 市場向心力分析:各流通管道

    第9章 全球失養型表皮分解性水泡症治療藥市場:各地區的分析、預測

    • 主要調查結果
    • 市場規模:各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲
    • 市場向心力分析:各國/各地區

    第10章 北美市場分析與預測

    • 簡介
      • 主要調查結果
    • 市場規模與其預測:治療藥材類別 (2018∼2030年)
    • 市場規模與其預測:疾病的各類型 (2018∼2030年)
    • 市場規模與其預測:各流通管道 (2018∼2030年)
    • 市場規模與其預測:各國 (2018∼2030年)
      • 美國
      • 加拿大
    • 市場向心力分析:治療藥的各類型,疾病的各類型,各流通管道,各國

第11章 歐洲市場分析與預測

第12章 亞太地區市場分析與預測

第13章 南美市場分析與預測

第14章 中東、非洲市場分析與預測

第15章 競爭情形

  • 企業簡介
    • Krystal Biotech
    • Castle Creek Biosciences, Inc.
    • Abeona Therapeutics, Inc.
    • Amryt Pharma plc
    • Wings Therapeutics
    • Phoenix Tissue Repair
    • InMed Pharmaceuticals, Inc.
    • RegeneRx
    • Holostem Terapie Avanzate Srl
目錄
Product Code: TMRGL79063

Title:
Dystrophic Epidermolysis Bullosa Treatment Market (Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, and Others; Disease Type: Dominant Dystrophic Epidermolysis Bullosa [DDEB] and Recessive Dystrophic Epidermolysis Bullosa [RDEB]; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030.

Dystrophic Epidermolysis Bullosa Treatment Market - Scope of the Report

TMR's report on the global dystrophic epidermolysis bullosa treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global dystrophic epidermolysis bullosa treatment market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global dystrophic epidermolysis bullosa treatment market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global dystrophic epidermolysis bullosa treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global dystrophic epidermolysis bullosa treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global dystrophic epidermolysis bullosa treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global dystrophic epidermolysis bullosa treatment market.

The report delves into the competition landscape of the global dystrophic epidermolysis bullosa treatment market. Key players operating in the global dystrophic epidermolysis bullosa treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global dystrophic epidermolysis bullosa treatment market that have been profiled in this report.

Key Questions Answered in Dystrophic Epidermolysis Bullosa Treatment Market Report

What is the scope of growth of companies present in the global dystrophic epidermolysis bullosa treatment market?

What will be the Y-o-Y growth of the global dystrophic epidermolysis bullosa treatment market between 2020 and 2030?

What is the influence of changing trends in technologies on the global dystrophic epidermolysis bullosa treatment market?

Will North America continue to be the most profitable market for dystrophic epidermolysis bullosa treatment providers?

Which factors are anticipated to hamper the growth of the global dystrophic epidermolysis bullosa treatment market during the forecast period?

Which are the leading companies in the global dystrophic epidermolysis bullosa treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global dystrophic epidermolysis bullosa treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global dystrophic epidermolysis bullosa treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the dystrophic epidermolysis bullosa treatment market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the dystrophic epidermolysis bullosa treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global dystrophic epidermolysis bullosa treatment market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global dystrophic epidermolysis bullosa treatment market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dystrophic Epidermolysis Bullosa Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Dystrophic Epidermolysis Bullosa Treatment Market Introduction
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, 2018-2030
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Novel Therapies for Dystrophic Epidermolysis Bullosa Treatment
  • 5.2. Pipeline Analysis
  • 5.3. Potential Market of Phase 3 Pipeline Drug Therapies for Dystrophic Epidermolysis Bullosa
  • 5.4. Epidemiology of Dystrophic Epidermolysis Bullosa
  • 5.5. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
  • 5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2018-2030
    • 6.3.1. Antibiotics
    • 6.3.2. Corticosteroids
    • 6.3.3. Opioid Analgesics
    • 6.3.4. Anticonvulsant
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Disease Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Disease Type, 2018-2030
    • 7.3.1. Dominant Dystrophic Epidermolysis Bullosa
    • 7.3.2. Recessive Dystrophic Epidermolysis Bullosa
  • 7.4. Market Attractiveness Analysis, by Disease Type

8. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2018-2030
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Country/Region

10. North America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2018-2030
    • 10.2.1. Antibiotics
    • 10.2.2. Corticosteroids
    • 10.2.3. Opioid Analgesics
    • 10.2.4. Anticonvulsant
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Disease Type, 2018-2030
    • 10.3.1. Dominant Dystrophic Epidermolysis Bullosa
    • 10.3.2. Recessive Dystrophic Epidermolysis Bullosa
  • 10.4. Market Value Forecast, by Distribution Channel, 2018-2030
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2018-2030
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment Type
    • 10.6.2. By Disease Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2.Market Value Forecast, by Treatment Type, 2018-2030
    • 11.2.1. Antibiotics
    • 11.2.2. Corticosteroids
    • 11.2.3. Opioid Analgesics
    • 11.2.4. Anticonvulsant
    • 11.2.5. Others
  • 11.3.Market Value Forecast, by Disease Type, 2018-2030
    • 11.3.1. Dominant Dystrophic Epidermolysis Bullosa
    • 11.3.2. Recessive Dystrophic Epidermolysis Bullosa
  • 11.4.Market Value Forecast, by Distribution Channel, 2018-2030
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5.Market Value Forecast, by Country/Sub-region, 2018-2030
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6.Market Attractiveness Analysis
    • 11.6.1. By Treatment Type
    • 11.6.2. By Disease Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2.Market Value Forecast, by Treatment Type, 2018-2030
    • 12.2.1. Antibiotics
    • 12.2.2. Corticosteroids
    • 12.2.3. Opioid Analgesics
    • 12.2.4. Anticonvulsant
    • 12.2.5. Others
  • 12.3.Market Value Forecast, by Disease Type, 2018-2030
    • 12.3.1. Dominant Dystrophic Epidermolysis Bullosa
    • 12.3.2. Recessive Dystrophic Epidermolysis Bullosa
  • 12.4.Market Value Forecast, by Distribution Channel, 2018-2030
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5.Market Value Forecast, by Country/Sub-region, 2018-2030
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6.Market Attractiveness Analysis
    • 12.6.1. By Treatment Type
    • 12.6.2. By Disease Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2.Market Value Forecast, by Treatment Type, 2018-2030
    • 13.2.1. Antibiotics
    • 13.2.2. Corticosteroids
    • 13.2.3. Opioid Analgesics
    • 13.2.4. Anticonvulsant
    • 13.2.5. Others
  • 13.3.Market Value Forecast, by Disease Type, 2018-2030
    • 13.3.1. Dominant Dystrophic Epidermolysis Bullosa
    • 13.3.2. Recessive Dystrophic Epidermolysis Bullosa
  • 13.4.Market Value Forecast, by Distribution Channel, 2018-2030
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5.Market Value Forecast, by Country/Sub-region, 2018-2030
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6.Market Attractiveness Analysis
    • 13.6.1. By Treatment Type
    • 13.6.2. By Disease Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast

  • 14.1.Introduction
    • 14.1.1. Key Findings
  • 14.2.Market Value Forecast, by Treatment Type, 2018-2030
    • 14.2.1. Antibiotics
    • 14.2.2. Corticosteroids
    • 14.2.3. Opioid Analgesics
    • 14.2.4. Anticonvulsant
    • 14.2.5. Others
  • 14.3.Market Value Forecast, by Disease Type, 2018-2030
    • 14.3.1. Dominant Dystrophic Epidermolysis Bullosa
    • 14.3.2. Recessive Dystrophic Epidermolysis Bullosa
  • 14.4.Market Value Forecast, by Distribution Channel, 2018-2030
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others
  • 14.5.Market Value Forecast, by Country/Sub-region, 2018-2030
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6.Market Attractiveness Analysis
    • 14.6.1. By Treatment Type
    • 14.6.2. By Disease Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competitive Landscape

  • 15.1. Company Profiles
    • 15.1.1. Krystal Biotech
      • 15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.1.2. Growth Strategies
      • 15.1.1.3. SWOT Analysis
    • 15.1.2. Castle Creek Biosciences, Inc.
      • 15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.2.2. Growth Strategies
      • 15.1.2.3. SWOT Analysis
    • 15.1.3. Abeona Therapeutics, Inc.
      • 15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.3.2. Growth Strategies
      • 15.1.3.3. SWOT Analysis
    • 15.1.4. Amryt Pharma plc
      • 15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.4.2. Growth Strategies
      • 15.1.4.3. SWOT Analysis
    • 15.1.5. Wings Therapeutics
      • 15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.5.2. Growth Strategies
      • 15.1.5.3. SWOT Analysis
    • 15.1.6. Phoenix Tissue Repair
      • 15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.6.2. Growth Strategies
      • 15.1.6.3. SWOT Analysis
    • 15.1.7. InMed Pharmaceuticals, Inc.
      • 15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.7.2. Growth Strategies
      • 15.1.7.3. SWOT Analysis
    • 15.1.8. RegeneRx
      • 15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.8.2. Growth Strategies
      • 15.1.8.3. SWOT Analysis
    • 15.1.9. Holostem Terapie Avanzate S.r.l.
      • 15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.1.9.2. Growth Strategies
      • 15.1.9.3. SWOT Analysis

List of Tables

  • Table 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2018-2030
  • Table 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Region, 2018-2030
  • Table 05: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 06: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018-2030
  • Table 07: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 08: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 09: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 10: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018-2030
  • Table 11: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 12: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018-2030
  • Table 13: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 14: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018-2030
  • Table 15: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 16: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 17: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 18: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018-2030
  • Table 19: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 20: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018-2030
  • Table 21: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 22: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018-2030
  • Table 23: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018-2030
  • Table 24: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030

List of Figure

  • Figure 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Disease Type, 2019
  • Figure 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Region, 2019
  • Figure 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Treatment Type, 2019
  • Figure 05: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Distribution Channel, 2019
  • Figure 06: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
  • Figure 07: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Treatment Type, 2020-2030
  • Figure 08: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Antibiotics, 2018-2030
  • Figure 09: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Transport Medium, 2018-2030
  • Figure 10: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Opioid Analgesics, 2018-2030
  • Figure 11: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Anticonvulsant, 2018-2030
  • Figure 12: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Others, 2018-2030
  • Figure 13: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
  • Figure 14: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 15: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Dominant Dystrophic Epidermolysis Bullosa (DDEB), 2018-2030
  • Figure 16: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Recessive Dystrophic Epidermolysis Bullosa (RDEB), 2018-2030
  • Figure 17: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 18: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 19: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018-2030
  • Figure 20: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018-2030
  • Figure 21: Global Dystrophic Epidermolysis Bullosa Treatment Market Revenue (US$ Mn), by Others, 2018-2030
  • Figure 22: Global Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Region, 2019 and 2030
  • Figure 23: Global Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Region, 2020-2030
  • Figure 24: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 25: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019-2030
  • Figure 26: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2030
  • Figure 27: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
  • Figure 28: North America Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019-2030
  • Figure 29: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
  • Figure 30: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 31: North America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
  • Figure 32: North America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 33: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 34: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019-2030
  • Figure 35: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2030
  • Figure 36: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
  • Figure 37: Europe Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019-2030
  • Figure 38: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
  • Figure 39: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 40: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
  • Figure 41: Europe Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 42: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 43: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019-2030
  • Figure 44: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2030
  • Figure 45: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
  • Figure 46: Asia Pacific Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019-2030
  • Figure 47: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
  • Figure 48: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 49: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
  • Figure 50: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 51: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 52: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019-2030
  • Figure 53: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2030
  • Figure 54: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
  • Figure 55: Latin America Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019-2030
  • Figure 56: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
  • Figure 57: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 58: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
  • Figure 59: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 60: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 61: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share, by Country/Sub-region, 2019-2030
  • Figure 62: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2030
  • Figure 63: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share Analysis, by Treatment Type, 2019 and 2030
  • Figure 64: Middle East & Africa Pressure Relief Device Market Attractiveness Analysis, by Treatment Type, 2019-2030
  • Figure 65: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Disease Type, 2019 and 2030
  • Figure 66: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Disease Type, 2020-2030
  • Figure 67: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030
  • Figure 68: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Attractiveness Analysis, by Distribution Channel, 2020-2030